Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STAR-0215 in healthy adults
NCT05477160Phase 1Completed
- Sponsor
- Astria Therapeutics
- Start
- Jul 2022
- Primary completion
- Nov 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of navenibart in hereditary angioedema (HAE) (5 arms), sponsored by Astria Therapeutics. Primary endpoint: Number of Participants Experiencing Treatment-emergent Adverse Events. Started Jul 2022; status: completed.
02
Drugs
navenibart
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NCT05477160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05477160.